NF-κB signaling in skeletal muscle: Prospects for intervention in muscle diseases

Journal of Molecular Medicine

Volumn 86, Issue 7, 2008, Pages 747-759

  Mourkioti, Foteini ^a   Rosenthal, Nadia ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

Author keywords

Genetic and pharmacological models; Muscle diseases; NF B transcription factor

Indexed keywords

CALPAIN 3; CREATINE KINASE MM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCLE RING FINGER 1 PROTEIN; MYOD PROTEIN; PROTEIN BAX; PROTEIN BCL 3; PROTEIN P100; PROTEIN P50; PROTEIN P52; PROTEIN P75; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN PROTEIN LIGASE E3; UNINDEXED DRUG;

ADAPTATION; AGING; CELL PROLIFERATION; CELL SURVIVAL; DERMATOMYOSITIS; DUCHENNE MUSCULAR DYSTROPHY; EXERCISE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; INFLAMMATION; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DENERVATION; MUSCLE DEVELOPMENT; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; POLYMYOSITIS; PROTEIN ANALYSIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; METABOLISM; MUSCLE DISEASE; SKELETAL MUSCLE;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCULAR DISEASES; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 46149126918     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0308-4     Document Type: Review

References (104)

1. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2(10):725-734
2. Perkins ND (2004) NF-kappaB: tumor promoter or suppressor. Trends Cell Biol 14(2):64-69
3. Baghdiguian S et al (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 5(5):503-511
4. Cai D et al (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119(2):285-298
5. Mourkioti F et al (2006) Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 116(11):2945-2954
6. Nenci A et al (2006) Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum Mol Genet 15(4):531-542
7. van Loo G et al (2006) Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol 7(9):954-961
8. Gareus R et al (2007) Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nat Cell Biol 9(4):461-469
9. Ventura JJ et al (2007) p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39(6):750-758
10. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260
11. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195-2224
12. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006(357):re13
13. Schmitz ML, Baeuerle PA (1991) The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 10(12):3805-3817
14. Betts JC, Nabel GJ (1996) Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences. Mol Cell Biol 16(11):6363-6371
15. Fan CM, Maniatis T (1991) Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature 354(6352):395-398
16. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8(1):49-62
17. Birbach A et al (2002) Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 277(13):10842-10851
18. Dechend R et al (1999) The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18(22):3316-3323
19. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96
20. Zandi E et al (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91(2):243-252
21. Yamaoka S et al (1998) Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93(7):1231-1240
22. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7(8):758-765
23. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6):280-288
24. Anest V et al (2003) A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423(6940):659-663
25. Yamamoto Y et al (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423(6940):655-659
26. Park KJ et al (2005) Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18(1):71-82
27. Albanese C et al (2003) IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 14(2):585-599
28. Kwak YT et al (2005) IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem 280(40):33945-33952
29. Hu Y et al (2001) IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410(6829):710-714
30. Ohazama A et al (2004) A dual role for Ikk alpha in tooth development. Dev Cell 6(2):219-227
31. Hu MC et al (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117(2):225-237
32. Gringhuis SI et al (2005) Convergent actions of I kappa B kinase beta and protein kinase C delta modulate mRNA stability through phosphorylation of 14-3-3 beta complexed with tristetraprolin. Mol Cell Biol 25(15):6454-6463
33. Wu ZH et al (2006) Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 311(5764):1141-1146
34. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7(5):353-364
35. Tanaka M et al (1999) Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10(4):421-429
36. Luedde T et al (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11(2):119-132
37. Kaltschmidt C et al (1994) Constitutive NF-kappa B activity in neurons. Mol Cell Biol 14(6):3981-3992
38. Mattson MP, Camandola S (2001) NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107(3):247-254
39. Kaufman CK, Fuchs E (2000) It's got you covered. NF-kappaB in the epidermis. J Cell Biol 149(5):999-1004
40. Pasparakis M et al (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417(6891):861-866
41. Nenci A et al (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446(7135):557-561
42. Du J et al (2000) Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J Biol Chem 275(26):19661-19666
43. Guttridge DC et al (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19(8):5785-5799
44. Judge AR et al (2007) Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol 292(1):C372-C382
45. Hunter RB, Kandarian SC (2004) Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114(10):1504-1511
46. Wang H et al (2007) NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 27(12):4374-4387
47. Bodine SC et al (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294(5547):1704-1708
48. Chen SE, Jin B, Li YP (2007) TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 292(5):C1660-C1671
49. Dogra C et al (2006) Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 281(15):10327-10336
50. Chen SE et al (2005) Role of TNF-{alpha} signaling in regeneration of cardiotoxin-injured muscle. Am J Physiol Cell Physiol 289(5):C1179-C1187
51. Langen RC et al (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 18(2):227-237
52. Ladner KJ, Caligiuri MA, Guttridge DC (2003) Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem 278(4):2294-2303
53. Langen RC et al (2002) Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol 283(3):C714-C721
54. Coletti D et al (2002) TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 21(4):631-642
55. Collins RA, Grounds MD (2001) The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem 49(8):989-1001
56. Layne MD, Farmer SR (1999) Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp Cell Res 249(1):177-187
57. Li YP (2003) TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 285(2):C370-C376
58. Miller SC et al (1988) Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol 8(6):2295-2301
59. Tracey KJ et al (1990) Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 86(6):2014-2024
60. Guttridge DC et al (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289(5488):2363-2366
61. Munz B et al (2002) RIP2, a checkpoint in myogenic differentiation. Mol Cell Biol 22(16):5879-5886
62. Yeh WC et al (1997) Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7(5):715-725
63. MacLachlan TK, Giordano A (1998) TRAF2 expression in differentiated muscle. J Cell Biochem 71(4):461-466
64. Kuroiwa Y et al (1996) Peg3 imprinted gene on proximal chromosome 7 encodes for a zinc finger protein. Nat Genet 12(2):186-190
65. Relaix F et al (1998) Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway. Nat Genet 18(3):287-291
66. Relaix F et al (1996) Pw1, a novel zinc finger gene implicated in the myogenic and neuronal lineages. Dev Biol 177(2):383-396
67. Lluis F et al (2006) Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 16(1):36-44
68. Li YP et al (2003) TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17(9):1048-1057
69. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21(4):245-273
70. Baeza-Raja B, Munoz-Canoves P (2004) p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 15(4):2013-2026
71. Moldawer LL et al (1987) Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am J Physiol 253(6 Pt 1):C766-C773
72. Alzuherri H, Chang KC (2003) Calcineurin activates NF-kappaB in skeletal muscle C2C12 cells. Cell Signal 15(5):471-478
73. Jackman RW, Kandarian SC (2004) The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 287(4):C834-C843
74. McKinnell IW, Rudnicki MA (2004) Molecular mechanisms of muscle atrophy. Cell 119(7):907-910
75. Hunter RB et al (2002) Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J 16(6):529-538
76. Cuthbertson D et al (2005) Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J 19(3):422-424
77. Emery AE (2002) The muscular dystrophies. Lancet 359(9307):687-695
78. Bulfield G et al (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81(4):1189-1192
79. Mourkioti F, Rosenthal N (2005) IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 26(10):535-542
80. Porter JD et al (2002) A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11(3):263-272
81. Monici MC et al (2003) Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60(6):993-997
82. Porter JD et al (2003) Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 13(3):223-235
83. Acharyya S et al (2007) Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117(4):889-901
84. Baghdiguian S et al (2001) Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IkappaBalpha/NF-kappaB survival pathway in skeletal muscle. J Mol Med 79(5-6):254-261
85. Figarella-Branger D et al (2003) Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28(6):659-682
86. Yang CC et al (1998) Immunolocalization of transcription factor NF-kappaB in inclusion-body myositis muscle and at normal human neuromuscular junctions. Neurosci Lett 254(2):77-80
87. Spencer MJ, Marino MW, Winckler WM (2000) Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 10(8):612-619
88. Rohl M et al (2004) Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest 113(3):474-481
89. Gilmore TD, Herscovitch M (2006) Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25(51):6887-6899
90. Grounds MD, Torrisi J (2004) Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18(6):676-682
91. Grounds MD et al (2005) Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 320(3):509-515
92. Coletti D et al (2005) Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis 43(3):120-128
93. Messina S et al (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 198(1):234-241
94. Balasubramanian S, Eckert RL (2007) Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J Biol Chem 282(9):6707-6715
95. Kang ES et al (2007) Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic Biol Med 43(4):535-545
96. Zipper LM, Mulcahy RT (2003) Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. Toxicol Sci 73(1):124-134
97. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265(5174):956-959
98. Amann R, Peskar BA (2002) Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447(1):1-9
99. Goldberg RM et al (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13(11):2856-2859
100. Gordon JN et al (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54(4):540-545
101. Girgenrath M et al (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25(24):5826-5839
102. Thaloor D et al (1999) Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 277(2 Pt 1):C320-C329
103. Warren GL et al (2002) Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J 16(12):1630-1632
104. Clinical Trials.gov Identifier:NCT00102453. Pentoxifylline in Duchenne muscular dystrophy (phase II)